Amorphous PARP Inhibitor Solid Dispersion for Oral Bioavailability

The patent transforms the physical state of the PARP-1 inhibitor from crystalline to amorphous form, fundamentally changing its dissolution properties. This parameter change enables the compound to achieve both improved water solubility and acceptable manufacturing stability by eliminating the rigid crystal lattice that limits solubility while maintaining solid-state stability through amorphous matrix formation.

The patent creates composite amorphous solid dispersion systems combining the PARP-1 inhibitor with polymers and surfactants. This composite approach allows the hydrophobic drug molecule to be dispersed within a hydrophilic matrix, significantly enhancing water solubility and bioavailability while the polymer network provides structural stability for manufacturing.

The patent utilizes parameter changes by controlling processing conditions (temperature, solvent composition, drying parameters) to directly form amorphous solid dispersions during manufacturing. This approach simplifies the overall process by eliminating separate amorphization steps and integrating formulation and processing into a single operation.

The patent employs polymers and surfactants as intermediary materials that facilitate the formation of amorphous dispersions and stabilize the drug in the amorphous state. These intermediaries act as mediators between the hydrophobic drug and aqueous environment, enabling improved bioavailability without requiring complex formulation procedures.